🔗 Share this article

Given that America continues making unprecedented adjustments to its vaccine recommendations, an unexpected name has surfaced somewhat surprisingly: Tracy Beth Høeg, a Danish American sports medicine doctor and public health researcher who initially gained attention by expressing skepticism about Covid vaccines in the global health crisis and has zeroed in on possible deaths following Covid immunization in her brief position at the Food and Drug Administration.

Planned Changes to Pediatric Vaccine Schedule

Health officials had intended to reveal major revisions to the pediatric vaccine schedule earlier this month, bringing the US with the Danish vaccine program, it is understood – a major change that would put the US out of step with much of the global community with little proof for benefit. The planned update has been delayed until the next year.

Instead of the top vaccines chief, Dr. Høeg is listed to speak at the gathering. She was just designated interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to run the division this calendar year.

A Shift at the Agency

The acting appointment could signify a closer partnership between the pharmaceutical and biologics divisions as Høeg and Prasad strengthen their influence at the FDA – and it points to a increased emphasis upon reevaluating already-approved vaccines at the FDA.

Dr. Høeg has often pushed for discontinuing certain pediatric vaccine recommendations in the US so as to align more in line with Denmark, a society with universal health coverage and a citizenry about the size of Wisconsin’s.

In her initial statements, she has persisted in emphasizing on vaccines – usually the purview of Prasad, director of the FDA’s vaccine center – instead of drug regulation.

Concerns Over Expertise

Dr. Høeg has little discernible background in medication creation, oversight or administrative roles, which has been typical for past heads of the biologics center. She has worked at the FDA as a top consultant to the agency head and CBER since earlier this year.

“She doesn’t seem to have the requisite experience” for leading the pharmaceutical oversight division, remarked Jonathan Howard. “She lacks experience running a randomized controlled trial. She lacks experience in leading a major agency. She is not an expert in drug approvals.”

Previous heads of the center would “understand laws and regulations and the research of pharmaceutical innovation”, commented a former acting FDA commissioner. “Objectively, she lacks the sort of resume that previous people who headed the center have had.”

The drug center has an enormous range of responsibilities at the agency, the former commissioner stated.

“Everybody just zeroes in on the novel medication approvals, but the generic drug division authorizes numerous generic drugs. There’s a biosimilars division, over-the-counter program and so forth, and all of those must be managed,” Woodcock noted. “The area you overlook, that is the part that I always told people is going to bite you.”

There is also, a significant administrative component to the role, which oversees more than 5,000 staff members. “It is a massive leadership role, if you do it right,” Woodcock concluded.

Official Statement and Disputed Initiatives

Regarding questions about Dr. Høeg's fitness for the role and whether this appointment indicates increased cooperation among regulatory chiefs on immunizations, a representative responded that the “concerns rely on flawed premises”.

“Her resume is consistent with the responsibilities of her job,” the spokesperson explained, pointing to the period Høeg spent advising the FDA commissioner on “drug safety and approval science, including computational safety modeling and vaccine surveillance”.

As the temporary head, Høeg takes over the commissioner’s controversial priority voucher program, a disputed expedited drug-approval program that allegedly troubled her predecessors. “How are these therapies being selected for this voucher program? Who takes the decisions?” Dr. Howard questioned. “There is a lot of secrecy occurring at the agency right now.”

Broadly speaking, he remarked, “the Food and Drug Administration appears to be shifting towards less stringent oversight of most medications, aside from immunizations.”

Public Past Work on Immunizations

Concerning immunizations, Dr. Høeg has a more documented, if problematic, past, some experts said. She published a research paper using non-validated crowd-sourced reports to assess the incidence of myocarditis following Covid immunization. She consulted for the Florida chief medical officer Dr. Joseph Ladapo, who was said to have modified findings to indicate COVID-19 vaccinations are pose a greater threat than they are.

Among her “wish list” for the incoming administration encompassed altering guidelines for recently developed shots and halting “optional” immunizations, she stated following the vote on a podcast. At the agency, Høeg has according to sources floated the idea of excluding young men from obtaining COVID-19 vaccinations.

“She is an all-around ideologue who begins with her preconceived notions and works backwards to accommodate the evidence in a highly misleading, fraudulent fashion,” Dr. Howard said.

Consolidating Power and a “Revenge Tour”

Høeg aligned with other skeptics, {like|